| Bioactivity | RIPGBM is a selective inducer of apoptosis in glioblastoma multiforme (GBM) cancer stem cells (CSCs) with an EC50 of ≤500 nM[1]. | ||||||||||||
| Invitro | RIPGBM induces caspase 1-dependent apoptosis by binding to receptor-interacting protein kinase 2 (RIPK2) and acting as a molecular switch, which reduces the formation of a prosurvival RIPK2/ TAK1 complex and increases the formation of a proapoptotic RIPK2/caspase 1 complex[1]. | ||||||||||||
| Name | RIPGBM | ||||||||||||
| CAS | 355406-76-7 | ||||||||||||
| Formula | C26H21FN2O3 | ||||||||||||
| Molar Mass | 428.45 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
RIPGBM
CAS: 355406-76-7 F: C26H21FN2O3 W: 428.45
RIPGBM is a selective inducer of apoptosis in glioblastoma multiforme (GBM) cancer stem cells (CSCs) with an EC50 of ≤5
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.